27456062|t|Somatic Therapy of a Mouse SMA Model with a U7 snRNA Gene Correcting SMN2 Splicing
27456062|a|Spinal Muscular Atrophy is due to the loss of SMN1 gene function. The duplicate gene SMN2 produces some, but not enough, SMN protein because most transcripts lack exon 7. Thus, promoting the inclusion of this exon is a therapeutic option. We show that a somatic gene therapy using the gene for a modified U7 RNA which stimulates this splicing has a profound and persistent therapeutic effect on the phenotype of a severe Spinal Muscular Atrophy mouse model. To this end, the U7 gene and vector and the production of pure, highly concentrated self-complementary (sc) adenovirus - associated virus 9 vector particles were optimized. Introduction of the functional vector into motoneurons of newborn Spinal Muscular Atrophy mice by intracerebroventricular injection led to a highly significant, dose-dependent increase in life span and improvement of muscle functions. Besides the central nervous system, the therapeutic U7 RNA was expressed in the heart and liver which may additionally have contributed to the observed therapeutic efficacy. This approach provides an additional therapeutic option for Spinal Muscular Atrophy and could also be adapted to treat other diseases of the central nervous system with regulatory small RNA genes.
27456062	0	15	Somatic Therapy	T061	C0037645
27456062	21	26	Mouse	T015	C0025929
27456062	27	30	SMA	T047	C0026847
27456062	31	36	Model	T050	C0012644
27456062	44	57	U7 snRNA Gene	T028	C2678677
27456062	69	73	SMN2	T028	C1420258
27456062	74	82	Splicing	T045	C0035687
27456062	83	106	Spinal Muscular Atrophy	T047	C0026847
27456062	110	116	due to	T169	C0678226
27456062	121	125	loss	T081	C1517945
27456062	129	133	SMN1	T028	C1420257
27456062	134	147	gene function	T045	C0314627
27456062	153	167	duplicate gene	T028	C0600497
27456062	168	172	SMN2	T028	C1420258
27456062	204	215	SMN protein	T116,T123	C4283935
27456062	229	240	transcripts	T114	C1519595
27456062	246	252	exon 7	T114,T123	C0015295
27456062	274	283	inclusion	T080	C1512693
27456062	292	296	exon	T114,T123	C0015295
27456062	302	313	therapeutic	T169	C0302350
27456062	314	320	option	T169	C1518601
27456062	337	357	somatic gene therapy	T061	C0037645
27456062	358	363	using	T169	C1524063
27456062	368	372	gene	T028	C0017337
27456062	379	394	modified U7 RNA	T028	C2678677
27456062	417	425	splicing	T045	C0035687
27456062	432	440	profound	T080	C0439808
27456062	445	455	persistent	T079	C0205322
27456062	456	474	therapeutic effect	T201	C1527144
27456062	482	491	phenotype	T032	C0031437
27456062	497	503	severe	T080	C0205082
27456062	504	527	Spinal Muscular Atrophy	T047	C0026847
27456062	528	539	mouse model	T050	C2986594
27456062	558	565	U7 gene	T028	C2678677
27456062	570	576	vector	T114	C0017397
27456062	599	603	pure	T080	C0205556
27456062	605	611	highly	T080	C0205250
27456062	625	659	self-complementary (sc) adenovirus	T005	C0001483
27456062	662	672	associated	T080	C0332281
27456062	673	680	virus 9	T005	C0001483
27456062	681	697	vector particles	T121	C1520007
27456062	703	712	optimized	T052	C2698650
27456062	734	744	functional	T169	C0205245
27456062	745	751	vector	T114	C0017397
27456062	757	768	motoneurons	T025	C0026609
27456062	772	779	newborn	T079	C2939425
27456062	780	803	Spinal Muscular Atrophy	T047	C0026847
27456062	804	808	mice	T015	C0025929
27456062	812	835	intracerebroventricular	T082	C0595818
27456062	836	845	injection	T061	C1533685
27456062	855	873	highly significant	T080	C1299395
27456062	875	889	dose-dependent	T081	C1512045
27456062	890	898	increase	T169	C0442805
27456062	902	911	life span	T102	C0870809
27456062	916	927	improvement	T077	C2986411
27456062	931	947	muscle functions	T042	C0231484
27456062	961	983	central nervous system	T022	C3714787
27456062	989	1000	therapeutic	T169	C0302350
27456062	1001	1007	U7 RNA	T028	C2678677
27456062	1012	1021	expressed	T045	C0017262
27456062	1029	1034	heart	T023	C0018787
27456062	1039	1044	liver	T023	C0023884
27456062	1073	1084	contributed	T052	C1880177
27456062	1092	1100	observed	T169	C1441672
27456062	1101	1121	therapeutic efficacy	T080	C2348767
27456062	1128	1136	approach	T082	C0449445
27456062	1137	1145	provides	T052	C1999230
27456062	1149	1159	additional	T169	C1524062
27456062	1160	1171	therapeutic	T169	C0302350
27456062	1172	1178	option	T169	C1518601
27456062	1183	1206	Spinal Muscular Atrophy	T047	C0026847
27456062	1236	1241	treat	T061	C0087111
27456062	1242	1247	other	T080	C0205394
27456062	1248	1256	diseases	T047	C0012634
27456062	1264	1286	central nervous system	T022	C3714787
27456062	1292	1318	regulatory small RNA genes	T028	C0017337